BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28004976)

  • 1. Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer.
    Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
    AJR Am J Roentgenol; 2017 Mar; 208(3):687-694. PubMed ID: 28004976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients.
    Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
    Acta Radiol; 2016 Jul; 57(7):802-8. PubMed ID: 26516288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
    Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
    Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
    Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
    Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
    Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
    Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence.
    Lee YJ; Youn IK; Kim SH; Kang BJ; Park WC; Lee A
    Magn Reson Imaging; 2020 Feb; 66():36-41. PubMed ID: 31785544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
    Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
    J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of breast-conserving treatment for triple-negative breast cancer].
    Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes.
    Hayashi Y; Satake H; Ishigaki S; Ito R; Kawamura M; Kawai H; Iwano S; Naganawa S
    Br J Radiol; 2020 Feb; 93(1106):20190712. PubMed ID: 31821036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
    Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
    Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
    Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
    PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
    Kamiya S; Satake H; Hayashi Y; Ishigaki S; Ito R; Kawamura M; Taoka T; Iwano S; Naganawa S
    Breast Cancer; 2022 Jan; 29(1):164-173. PubMed ID: 34529241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence.
    Bae MS; Moon HG; Han W; Noh DY; Ryu HS; Park IA; Chang JM; Cho N; Moon WK
    Radiology; 2016 Feb; 278(2):356-64. PubMed ID: 26230976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran.
    Mousavi SA; Kasaeian A; Pourkasmaee M; Ghavamzadeh A; Alimoghaddam K; Vaezi M; Kamranzadeh Fumani H; Babakhani D; Tavakoli S
    PLoS One; 2019; 14(1):e0208701. PubMed ID: 30608935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients.
    Bozkurt O; Karaca H; Berk V; Inanc M; Ocak Duran A; Ozaslan E; Ucar M; Ozkan M
    J BUON; 2015; 20(6):1432-9. PubMed ID: 26854438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of transforming growth factor-β1 in triple negative breast cancer patients.
    Zhang M; Wu J; Mao K; Deng H; Yang Y; Zhou E; Liu J
    Int J Surg; 2017 Sep; 45():72-76. PubMed ID: 28754615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.
    Wang H; Zhan W; Chen W; Li Y; Chen X; Shen K
    Breast; 2020 Feb; 49():33-40. PubMed ID: 31677531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor.
    Sebastián Sebastián C; García Mur C; Cruz Ciria S; Rosero Cuesta DS; Gros Bañeres B
    Radiologia; 2016; 58(4):283-93. PubMed ID: 27064084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.